Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE:002317)
China · Delayed Price · Currency is CNY 18.94
+0.18 (0.96%)
Feb 3, 2026, 1:25 PM CST
SHE:002317 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,425 | 2,444 | 2,600 | 2,665 | 2,416 | 1,888 |
Other Revenue | 23.35 | 23.35 | 10.39 | 10.72 | 12.74 | 7.79 |
| 2,448 | 2,467 | 2,611 | 2,676 | 2,429 | 1,896 | |
Revenue Growth (YoY) | 0.03% | -5.48% | -2.45% | 10.17% | 28.13% | -25.11% |
Cost of Revenue | 1,113 | 1,135 | 1,081 | 941.57 | 813.75 | 658.79 |
Gross Profit | 1,335 | 1,332 | 1,529 | 1,735 | 1,615 | 1,237 |
Selling, General & Admin | 988.12 | 1,002 | 1,046 | 1,172 | 1,086 | 852.17 |
Research & Development | 85.03 | 111.2 | 127.37 | 156.59 | 136.73 | 113.62 |
Other Operating Expenses | -6.29 | 8.49 | 11.49 | 24.14 | 24.06 | 17.47 |
Operating Expenses | 1,069 | 1,125 | 1,183 | 1,354 | 1,247 | 983.26 |
Operating Income | 265.27 | 206.95 | 346.21 | 380.45 | 368.16 | 253.77 |
Interest Expense | -5.63 | -25.35 | -46.91 | -73.36 | -73.81 | -37.2 |
Interest & Investment Income | 26.73 | 43.64 | 54.14 | 73.98 | 46.75 | 127.33 |
Currency Exchange Gain (Loss) | -1.4 | -1.4 | 0 | -10.65 | -0.79 | 0.61 |
Other Non Operating Income (Expenses) | 57.56 | -1.22 | -2.28 | -2.77 | 0.81 | -0.01 |
EBT Excluding Unusual Items | 342.52 | 222.61 | 351.16 | 367.64 | 341.12 | 344.5 |
Impairment of Goodwill | -201.68 | -201.68 | - | - | - | -845.26 |
Gain (Loss) on Sale of Investments | -31.1 | -18.22 | -65.23 | -19.51 | -66.73 | 137.98 |
Gain (Loss) on Sale of Assets | 4.78 | 0.03 | 21.68 | 14.69 | -0.63 | 0.57 |
Asset Writedown | -300.39 | -299.21 | -30.56 | -2.83 | -2.22 | -16.46 |
Other Unusual Items | -40.4 | -39.41 | 6.6 | 8.3 | 37.94 | 33.41 |
Pretax Income | -226.27 | -335.88 | 283.66 | 368.3 | 309.48 | -345.27 |
Income Tax Expense | 38.11 | 38.08 | 33.76 | 52.95 | 34.81 | 89.16 |
Earnings From Continuing Operations | -264.38 | -373.96 | 249.9 | 315.35 | 274.67 | -434.43 |
Minority Interest in Earnings | 67 | 74.81 | 13.37 | 6.7 | 2.96 | 7.82 |
Net Income | -197.38 | -299.16 | 263.27 | 322.05 | 277.63 | -426.61 |
Net Income to Common | -197.38 | -299.16 | 263.27 | 322.05 | 277.63 | -426.61 |
Net Income Growth | - | - | -18.25% | 16.00% | - | - |
Shares Outstanding (Basic) | 837 | 831 | 823 | 805 | 793 | 805 |
Shares Outstanding (Diluted) | 837 | 831 | 823 | 805 | 793 | 805 |
Shares Change (YoY) | 1.36% | 1.00% | 2.19% | 1.50% | -1.45% | -1.20% |
EPS (Basic) | -0.24 | -0.36 | 0.32 | 0.40 | 0.35 | -0.53 |
EPS (Diluted) | -0.24 | -0.36 | 0.32 | 0.40 | 0.35 | -0.53 |
EPS Growth | - | - | -20.00% | 14.29% | - | - |
Free Cash Flow | -83.53 | 109.58 | -172.44 | -204.89 | 409 | -15.5 |
Free Cash Flow Per Share | -0.10 | 0.13 | -0.21 | -0.25 | 0.52 | -0.02 |
Dividend Per Share | 0.200 | 0.200 | 0.200 | 0.200 | 0.200 | 0.200 |
Gross Margin | 54.52% | 53.99% | 58.58% | 64.82% | 66.50% | 65.25% |
Operating Margin | 10.84% | 8.39% | 13.26% | 14.22% | 15.16% | 13.39% |
Profit Margin | -8.06% | -12.12% | 10.08% | 12.03% | 11.43% | -22.50% |
Free Cash Flow Margin | -3.41% | 4.44% | -6.61% | -7.66% | 16.84% | -0.82% |
EBITDA | 378.4 | 322.53 | 465.05 | 477.9 | 462.45 | 352.45 |
EBITDA Margin | 15.46% | 13.07% | 17.81% | 17.86% | 19.04% | 18.59% |
D&A For EBITDA | 113.13 | 115.58 | 118.84 | 97.45 | 94.29 | 98.67 |
EBIT | 265.27 | 206.95 | 346.21 | 380.45 | 368.16 | 253.77 |
EBIT Margin | 10.84% | 8.39% | 13.26% | 14.22% | 15.16% | 13.39% |
Effective Tax Rate | - | - | 11.90% | 14.38% | 11.25% | - |
Revenue as Reported | 2,448 | 2,467 | 2,611 | 2,676 | 2,429 | 1,896 |
Advertising Expenses | - | 15.4 | 5.9 | 6.39 | 6.79 | 2.91 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.